PRELIMINARY PROGRAMME NHOW MILAN
|
|
|
- Erik Malcolm Reed
- 5 years ago
- Views:
Transcription
1 PRELIMINARY PROGRAMME Via Tortona, Milan (Italy) 1
2 nd SCIENTIFIC PRELIMINARY PROGRAM Thursday, 18 October 2018 OPENING CEREMONY Chairs: M. Clerici (Italy), S. Esposito (Italy), A. Osterhaus (Germany) Welcome from the authorities WAidid activities Microbiota, environmental drivers, and health consequences D. Bogaert, UK BOARD CONGRESS PRESIDENT Susanna Esposito (Italy) WAIDID BOARD MEMBERS Francesco Blasi (Italy) Kathryn Edwards (USA) Ivan Hung (China) Irja Lutsar (Estonia) Shabir Madhi (South Africa) Miguel O Ryan (Chile) Albert Osterhaus (The Netherlands) Tina Tan (USA) Global health and inequality S. Vella, Italy Maternal immunisation T. Tan, USA Vaccinomics G. Poland, USA Welcome Cocktail 2 3
3 Friday, 19 October 2018 HOT TOPICS IN RESPIRATORY INFECTIONS Chairs: D. Bogaert (UK), G.B. Migliori (Italy) Innate and adaptive immunity in respiratory diseases K. Flanagan, Australia Tuberculosis: the importance of a global TB network G.B. Migliori, Italy Lumacaftor and ivacaftor in patients with cystic fibrosis S. Aliberti, Italy NTM respiratory infections: from guidelines to real life C. Rodrigo, Spain Discussion Coffee break INFLUENZA AND ITS PREVENTION Chairs: M.R. Castrucci (Italy), H. Niesters (The Netherlands) Burden of influenza in the different age groups I. Hung, China Update on influenza vaccination A. Osterhaus, Germany Discussion LECTURE Introduction - W. Feleszko, Poland Inflammasome during infectious and non-infectious diseases M. Clerici, Italy WAidid CONSENSUS PAPER ON EFFICACY DIFFERENCES BETWEEN PCV10 AND PCV13 Chairs: J. Diez Domingo (Spain), S. Esposito (Italy) Streptococcus pneumoniae and differences between countries that use PCV10 and PCV13 A. Palmu, Finland Impact of pneumococcal vaccines on vaccine-type and non-vaccine type pneumococcal diseases P. De Wals, Canada PCV7 followed by PCV10: Dutch data on IPD and pneumonia E. Sanders, The Netherlands Discussion Light lunch IMMUNOMODULATORS AND RECURRENT RESPIRATORY TRACT INFECTIONS Chairs: L. Bernardo (Italy), E. Sanders (The Netherlands) Host-pathogen interaction in respiratory infections W. Feleszko, Poland Efficacy and safety of immunomodulators in pediatric age Discussion 4 5
4 Friday, 19 October 2018 Saturday, 20 October 2018 OPTIMIZING HEXAVALENT VACCINATION Chairs: S. Esposito (Italy), M. Knuf (Germany) MICROBIOMA AND INFECTIOUS DISEASES Chairs: I. Lutsar (Estonia), L. Romani (Italy) Mandatory vaccinations. The Italian experience Rationale of combined vaccines in infants and toddlers M. Knuf, Germany Hexavalent vaccines today J. Diez-Domingo, Spain Q&A Coffee break Microbiota and H pylori in children and cancer later in life: what pediatricians should know M. O Ryan, Chile Microbiome and immune response to vaccine P. Rossi, Italy New findings on virome in infectious diseases H. Niesters, The Netherlands Manipulating the microbiota to improve human health L. Romani, Italy HOW TO BETTER FIGHT PERTUSSIS Chairs: G. Poland (USA ), G. Rezza (Italy) Current vaccination coverage rates and strategies in EU P. Stefanelli, Italy The importance of booster vaccine doses throughout life How to succeed in maternal immunization G. Amirthalingam, UK Discussion Coffee break LECTURES Introduction: I. Lutsar (Estonia) Antimicrobial stewardship: a competency-based approach F. Menichetti, Italy New biomarkers in pneumonia F. Blasi, Italy 6 MENINGOCOCCAL PREVENTION STATE OF THE ART Chairs: N. Principi (Italy); M. O Ryan (Chile) Invasive meningococcal disease across the world M. O Ryan, Chile Meningococcal prevention in children and adolescents J. Diez-Domingo, Spain How to communicate on meningococcal prevention - Patient association and Public health point of view E. Moya, Spain ADVANCES IN ANTINFECTIVE THERAPY Chairs: F. Blasi (Italy), K. Flanagan (Australia) New PK data on antimicrobials for neonates and children: clinical implications I. Lutsar, Estonia Management of MDR and XDR TB G.B. Migliori, Italy From antimicrobial resistance to drug discovery V. Cecchetti, Italy Discussion 7
5 nd AIM Group International - Milan Office Via G. Ripamonti, MILAN (Italy) Phone Fax waidid2018@aimgroup.eu 8
7 th FIDSSA CONFERENCE 2017 Programme as at 11 May 2017 PROVISIONAL ACADEMIC PROGRAMME
THURSDAY 9 NOVEMBER 15h00 17h00 Conference Registration FIDSSA Official Opening Ceremony 17h00 17h15 Welcome & Opening - Marc Mendelson (FIDSSA President) PLENARY SESSION 1: Emerging and Re-Emerging Infectious
Version 1.11 of 20/07/2018
Version 1.11 of 20/07/2018 NICE JANUARY 17-19, 2019 6 th International Workshop on Lung Health New approaches to respiratory diseases PRESIDENTS: F. BLASI, G.W. CANONICA CHAIRMEN: S. CENTANNI, J.C. VIRCHOW,
Welcome to the 2 nd World Bronchiectasis Conference
FINAL PROGRAMME Version 1.1 of 11/05/2017 Organised by : Powered by : Welcome to the 2 nd World Bronchiectasis Conference Dear Colleagues, It is our great pleasure to invite you to contribute to the 2
Shabir A. Madhi. Global Overview of Maternal Immunisation
Shabir A. Madhi Global Overview of Maternal Immunisation National Institute for Communicable Diseases & University of Witwatersrand, South Africa Respiratory and Meningeal Pathogens Research Unit, & DST/NRF:
Organised by : Powered by :
Welcome to the 2 nd World Bronchiectasis Conference Dear Colleagues, It is our great pleasure to invite you to contribute to the 2 nd World Bronchiectasis Conference. Following a successful first edition
Impact and effectiveness of national immunisation programmes. David Green, Nurse Consultant, Immunisations Public Health England
Impact and effectiveness of national immunisation programmes David Green, Nurse Consultant, Immunisations Public Health England Session objectives Immunisation planning and implementation The impact and
14:30-16:30 SATS Council Meeting Venue: Hospitality 25
PATS & SATS 2018 CONGRESS 12-15 April 2018, Durban ICC, Sout: Africa Provisional Programme (subject to change) Thursday 12 April 7:00 Registration for pre-congress workshops open Outside workshop venues
Risk profiles and vaccine uptake in children with invasive pneumococcal disease at a tertiary hospital in Tshwane:
Risk profiles and vaccine uptake in children with invasive pneumococcal disease at a tertiary hospital in Tshwane: A retrospective review Xandré Dearden www.up.ac.za IPD: disease spectrum and epidemiology
Global and National Trends in Vaccine Preventable Diseases. Dr Brenda Corcoran National Immunisation Office.
Global and National Trends in Vaccine Preventable Diseases Dr Brenda Corcoran National Immunisation Office Global mortality 2008 Children under 5 years of age 1.5 million deaths due to vaccine preventable
ACIP Recommendation Update. Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego
ACIP Recommendation Update Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego What has ACIP been up to lately? New Recommendations Tdap vaccination for each pregnancy Meningococcal
Maternal Immunization Efficacy and Safety Saad B. Omer
Maternal Immunization Efficacy and Safety Saad B. Omer William H. Foege Professor of Global Health Professor of Epidemiology & Pediatrics Emory University, Schools of Public Health & Medicine Pregnancy
Childhood Vaccination and Immunisation
DIRECTORATE GENERAL FOR INTERNAL POLICIES POLICY DEPARTMENT A: ECONOMIC AND SCIENTIFIC POLICY WORKSHOP Childhood Vaccination and Immunisation Brussels, 19 June 2013 MEETING DOCUMENT Policy Department A:
Immunisation in people living with HIV. Dr Bernadett Gosnell, Department of Infectious Diseases, UKZN
Immunisation in people living with HIV Dr Bernadett Gosnell, Department of Infectious Diseases, UKZN Calculating immunisation s return on investment In Gavi-supported countries, 2011 2020 48x (full income
5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition
5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition SIXTH DRAFT OF THE PROGRAM AUGUST 28, 2014 Wednesday, October 5, 2016 08:00-16:30 Post Graduate course (To be developed by the
Why is surveillance important after introducing vaccines?
Why is surveillance important after introducing vaccines? Dr Michael Edelstein Immunisation Department, National Infections service Public Health England @epi_michael BSAC Spring conference, 12 th March
Tuberculosis Now! Jon S Friedland MA, FRCPE, FMedSci. Infectious Diseases & Immunity
Tuberculosis Now! Jon S Friedland MA, FRCPE, FMedSci Infectious Diseases & Immunity What is TB Now? Epidemiology including international migration Biomarkers New treatments TB notification rate per 1
Shabir A. Madhi Possibilities for reducing neonatal and young infant mortality through Maternal immunization
Shabir A. Madhi Possibilities for reducing neonatal and young infant mortality through Maternal immunization National Institute for Communicable Diseases & University of Witwatersrand, South Africa Respiratory
Product Development for Vaccines Advisory Committee:
Product Development for Vaccines Advisory Committee: Highlights from the 2016 year of vaccine development SAGE, October 2016 David C. Kaslow, MD Chair, Product Development for Vaccines Advisory Committee
PRELIMINARY PROGRAMME
Thursday, February 7 th, 2019 08:00 Registration 08:45 Opening A, Artigas, MD (Sabadell, Spain) J. Garnacho, MD (Sevilla, Spain) I. SEPSIS PRELIMINARY PROGRAMME Moderators: A. Artigas, MD (Sabadell, Spain)
Pneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections
Pneumococcal vaccination in UK: an update Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections Leading infectious causes of mortality, 2000 WHO estimates 3.5 Deaths
Full public health impact or. cherry-picking?
Full public health impact or cherry-picking? Arto Palmu, MD, PhD, Research manager, head of Clinical Research Team, Department of Public Health Solutions 10.11.2017 Arto Palmu / RIVM2017 1 Disclosure The
GSK VACCINES: KEY GROWTH DRIVERS
GSK VACCINES: KEY GROWTH DRIVERS Martin Andrews Senior Vice President, Global Vaccines Centre of Excellence, GSK Biologicals Millions of children die from infectious diseases Many of these deaths are preventable
PRELIMINARY PROGRAMME. 5 edition BERLIN ORGANISING SECRETARIAT
PRELIMINARY PROGRAMME th BERLIN 20-23 JUNE 2019 ORGANISING SECRETARIAT th SCIENTIFIC ORGANIZATION SPAO Sociedad de Pediatría de Andalucía Oriental y Extremadura PATRONEGE BERLIN 20-23 JUNE 2019 COMMITTEES
Communicable Disease & Immunization
Communicable Disease & Immunization Ingham County Health Surveillance Book 2016 Communicable Disease & Immunization - 1 Communicable Disease & Immunization T he control of communicable disease and immunization,
XDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps
XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever
Experience with maternal pertussis and PCV13 immunisation in England
Experience with maternal pertussis and PCV13 immunisation in England Immunisation, Hepatitis & Blood Safety department Public Health England 5th RIVM Vaccine Preventable Diseases Research day 18 th November
Thursday 1 December (The University Club of Western Australia Theatre Auditorium unless otherwise indicated)
Thursday 1 December (The University Club of Western Australia Theatre Auditorium unless otherwise indicated) 07:00am - 07:55am (0:55) 08:00am - 08:45am (0:45) 08:50am - 09:20am (0:30) Chair: A/Prof Peter
Would a combined PCV10+PCV13 immunization schedule be a cost-effective option for Canadian children?
Would a combined PCV10+PCV13 immunization schedule be a cost-effective option for Canadian children? Philippe De Wals Department of Social and Preventive Medicine, Laval University Quebec University Hospital
Pr Robert Cohen CHI Créteil France
EFFECT OF VACCINATION ON ANTIMICROBIAL RESISTANCE : THE EXAMPLE OF THE IMPACT OF PCVS ON ANTIBIOTIC RESISTANCE Pr Robert Cohen CHI Créteil France 1 DISCLOSURES I have received during the las 3 years honorarium
Outline. Why Adult Immunization Matters. Recommended Adult Vaccines: Age Based. Why Do We Vaccinate? Footnotes. Risk Based
Why Adult Immunization Matters Outline CDC Recommended Adult Vaccines Burden of U.S. adult vaccine preventable disease Vaccine effectiveness in adults Adult immunization coverage rates Ramifications of
BCG vaccine and tuberculosis
PART 2: Vaccination for special risk groups 2.1 Vaccination for Aboriginal and Torres Strait Islander people Aboriginal and Torres Strait Islander people historically had a very high burden of infectious
European Academy of Paediatrics 2017 Congress and MasterCourse (EAP 2017) Preliminary Programme * As of August 18, Thursday, October 12, 2017
Thursday, October 12, 2017 EAP 2017 MasterCourse Infectious Diseases 08:30-08:45 MasterCourse Welcome & Organizational Introduction Hall A 08:45-11:00 Group 1 11:00-11:30 Coffee Break Group 2 Group 3 MasterCourse
Essential Vaccinations for HIV-Positive Adults and Adolescents
Essential Vaccinations for HIV-Positive Adults and Adolescents Janak A. Patel, MD Professor & Director, Pediatric Infectious Diseases Director, Maternal-Child Program University of Texas Medical Branch
Faculty Disclosure. Stephen I. Pelton, MD. Dr. Pelton has listed no financial interest/arrangement that would be considered a conflict of interest.
Faculty Disclosure Stephen I. Pelton, MD Dr. Pelton has listed no financial interest/arrangement that would be considered a conflict of interest. Advances in the management of fever in infants 0 to 3 and
Selected vaccine introduction status into routine immunization
Selected introduction status into routine infant immunization worldwide, 2003 This report summarizes the current status of national immunization schedules in 2003, as reported by Member States in the /UNICEF
Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.
Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy
2016 Vaccine Preventable Disease Summary
2016 Vaccine Preventable Disease Summary 12251 James Street Holland, MI 49424 www.miottawa.org/healthdata Prepared October 2017 2016 Summary of Vaccine Preventable Diseases (VPDs) Reported to Ottawa County
Pneumococcal pneumonia
Pneumococcal pneumonia Wei Shen Lim Consultant Respiratory Physician & Honorary Professor of Medicine Nottingham University Hospitals NHS Trust University of Nottingham Declarations of interest Unrestricted
Shabir A. Madhi. Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality.
Shabir A. Madhi Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality. National Institute for Communicable Diseases & University of Witwatersrand,
Report from the Pertussis Working Group
Report from the Pertussis Working Group Elizabeth Miller SAGE Member and Chair of the Pertussis Working Group 29 October 2009 Geneva Working Group Members Elizabeth Miller (chair), Health Protection Agency,
SAGE Working Group on Pertussis Vaccines. Introduction and Session Overview
SAGE Working Group on Pertussis Vaccines Introduction and Session Overview C. A. Siegrist, SAGE Pertussis Working Group Chair SAGE Meeting April 1-3, 2014 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
SESSION 1: Epidemiology of IBI in the EU, an overview Chairman: Lucia Pastore Celentano (ECDC)
First Annual Meeting of the European Invasive Bacterial Infections Surveillance Network Stockholm, 17-18 March 2009 Tuesday March 17 th, 2009 10:30 Bus from the Hotel to ECDC 11:00-12:00 Registration and
Invasive meningococal diseasefocus on Meningococcal B - epidemiology, international and Ireland
Invasive meningococal diseasefocus on Meningococcal B - epidemiology, international and Ireland Dr Suzanne Cotter, Health Protection Surveillance Centre (HPSC) Scope presentation Meningococccal disease
Clinical. Update in Respiratory Medicine. International Symposium on. Barcelona (Spain) February 23 rd -24 th, 2018 FINAL PROGRAMME
With an unrestricted grant by Organized by Vall d Hebron Barcelona Hospital Campus Barcelona, Spain International FINAL PROGRAMME Respiratory diseases are among the most frequent causes of mortality and
Pertussis Surveillance Examples from Europe
Pertussis Surveillance Examples from Europe Johannes G. Liese Pediatric Infectious Diseases and Immunology University Childrens Hospital Julius-Maximilians-University, Würzburg, Germany 1 2 Pertussis Surveillance
CURRICULUM VITAE. Degree in Medicine and Surgery 27 July 1995, University of Milan (110/110 cum laude).
CURRICULUM VITAE Personal details Name: Susanna ESPOSITO, MD Address: Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione
Multicomponent MenB Vaccine (4CMenB): An Innovative Step In the Global Fight Against Serogroup B Meningococcal Disease
Multicomponent MenB Vaccine (4CMenB): An Innovative Step In the Global Fight Against Serogroup B Meningococcal Disease Jeffrey J. Stoddard, MD, FAAP Head, Global Medical Affairs Novartis Vaccines and Diagnostics
Benefits of the pneumococcal immunisation programme in children in the United Kingdom
Benefits of the pneumococcal immunisation programme in children in the United Kingdom 2006-2014 Professor Mary P E Slack mpeslack@gmail.com March 2015 Disclosure of interest The presenter has received
Invasive pneumococcal disease
SURVEILLANCE REPORT Annual Epidemiological Report for 2016 Invasive pneumococcal disease Key facts In 2016, 21 986 confirmed cases of invasive pneumococcal disease (IPD) were reported in the EU/EEA. The
EPNV-Montreux 2018: Preliminary Educational and Scientific Program
EPNV-Montreux 2018: Preliminary Educational and Scientific Program April 25-26, 2018: Pre-Conference Workshops Wednesday (April 25): 09 00 18 00 Thursday (April 26): 08 00 12 00 April 26-28, 2018: Main
27 th Nordic Medical History Congress
27 th Nordic Medical History Congress Wed 22 May Sat 25 May 2019 Organizing Committee Chairman: Ulrik Bak Kirk (Board Member) on behalf of the Danish Society for the History of Medicine (DMHS) #nmhc2019
(ACIP) 2018:28:69-76 DOI: /ICJ _28(2) (07)
69 1 2 1 2 (ACIP) B 2018:28:69-76 E 106 1 15 107 3 14 123 (07) 7317123 DOI: 10.6526/ICJ.201804_28(2).0003 107 4 70 [1] (Tdap) B E (estradiol) T (type 2 helper T-cell, Th2) T (type 1 helper T-cell, Th1)
WALTER MARGET EDUCATIONAL INDUSTRY SYMPOSIUM 4 WORKSHOP
SCIENCE TRACK EDUCATIONAL TRACK SCIENCE AND EDUCATIONAL TRACK SPONSORED SYMPOSIUM BREAKS AND NETWORKING EVENT ESPID MEMBER AGM HALL A HALL B HALL C HALL D INDUSTRY SYMPOSIUM 1 08:30-10:00 10:00-10:30 Coffee
Vaccine Innovation: Challenges and Opportunities to Protect Health. Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines
Vaccine Innovation: Challenges and Opportunities to Protect Health Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines Protecting Health with Vaccines HEALTH IMPROVEMENT Population Impact Guidelines
3.1 PHASE 2 OF THE GLOBAL PROJECT
RESULTS CHAPTER 3 3.1 PHASE 2 OF THE GLOBAL PROJECT (1996 1999) This new report of the Global Project provides data on anti-tuberculosis drug resistance from 58 geographical settings. Of these, 28 provided
Childhood Pneumonia & Meningitis: Recent Advances
Childhood Pneumonia & Meningitis: Recent Advances Karachi, Pakistan January 31, 2009 MEDIA COVERAGE DAWN KARACHI, Pakistan February 1, 2009 Experts pin hopes on pentavalent vaccines A programme to introduce
Food, Microbiota and Immunity "For strong immunity - feed your microbiota well" June 7-10, 2017, Castle Třešť, Czech Republic
Food, Microbiota and Immunity "For strong immunity - feed your microbiota well" June 7-10, 2017, Castle Třešť, Czech Republic Program: Wednesday June 7 14:00 Departure from Prague by bus: station metro
Current Status of PCV Use and WHO Recommendations
Current Status of PCV Use and WHO Recommendations SAGE 18 October 2017 Kate O Brien, MD MPH 1 Pneumonia remains a major cause of child deaths LMIC LMIC Pneumonia HIC HIC Pneumonia ~16% ~5% 2015 Black,
Social determinants of infectious diseases
Social determinants of infectious diseases Informal Health Council, 5-6 July 2011, Sopot, Poland President, Commissioner, Ministers, thank you for asking me to contribute to your debate. Over the next
2016 Academic Review for the New Zealand National Immunisation Schedule: Pneumococcal ten valent vaccine effectiveness and safety
2016 Academic Review for the New Zealand National Immunisation Schedule: Pneumococcal ten valent vaccine effectiveness and safety Prepared as part of a Ministry of Health contract for services by the Immunisation
Samir K Saha, Ph.D Child Health Research Foundation Dhaka Shishu Hospital Dhaka, Bangladesh
Barriers Rotavirus to Rotavirus Vaccine Impact Vaccine Beyond Preventing Introduction Diarrhea Samir K Saha, Ph.D Child Health Research Foundation Dhaka Shishu Hospital Dhaka, Bangladesh 13 th International
Invasive meningococcal disease
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Invasive meningococcal disease Key facts In 2015, 3 121 confirmed cases of invasive meningococcal disease were reported by 30 EU/EEA Member States
#4 (Tuberculosis OR TB OR Pulmonary Tuberculosis OR Multi-Drug Resistant Tuberculosis OR MDR OR Extremely-Drug Resistant Tuberculosis or XDR)
DATABASE Cochrane Database of Systematic Reviews DATE 15 DECEMBER 2015 #1 Safety of Crucell Ad35/ AERAS-402 OR Effectiveness of Crucell Ad35/ Aeras-402 OR Safety of MVA85A/ Aeras-485 OR Effectiveness of
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP
Living Today for a Better Tomorrow: Helping Adults Understand the Value of Immunization to Long term Health
Living Today for a Better Tomorrow: Helping Adults Understand the Value of Immunization to Long term Health National Foundation for Infectious Diseases Len Novick, Executive Director May 8, 2009 Adult
Craig Laferriere. The selection of pneumococcal serotypes for a developing-world vaccine: A metaregression analysis of immunogenicity
Craig Laferriere The selection of pneumococcal serotypes for a developing-world vaccine: A metaregression analysis of immunogenicity I have no actual or potential conflict of interest in relation to this
Using a mathematical model to evaluate the impact of different PCV schedules:
Using a mathematical model to evaluate the impact of different PCV schedules: Preliminary results from the West Africa epidemiological scenario Alessia Melegaro 1, Albert Jan van Hoek 2, Yoon Choi 2, Nigel
Pneumococcal vaccines. Safety & Efficacy. Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh
Pneumococcal vaccines Safety & Efficacy Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh Disclosure Slide X X I DO NOT have any significant or other financial relationships with industry
Communicable Disease. Introduction
Communicable Disease HIGHLIGHTS Seniors have the highest incidence rates of tuberculosis compared to other age groups. The incidence rates for TB have been higher among Peel seniors compared to Ontario
Barriers and drivers of seasonal influenza vaccination coverage in the EU. Elisabeth Nicand
Barriers and drivers of seasonal influenza vaccination coverage in the EU Elisabeth Nicand enicand@mesvaccins.net National Influenza schedule in Europe (www.ecdc/ vaccine scheduler) Influenza vaccination
Immunisation Update for Occupational Health
Immunisation Update for Occupational Health Dr Gayatri Amirthalingam Immunisation, Hepatitis & Blood Safety department Public Health England 29 th April 2016 Session Outline Epidemiology of vaccine preventable
2017/18 Immunisation programmes list of additional and enhanced services
2017/18 Immunisation programmes list of additional and enhanced services 2017/18 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2017 Prepared
International Society of Microbiota
Targeting Microbiota World Congress 2018 1 Targeting Microbiota World Congress 2018 2 Dear Colleagues, On behalf of the International Society of Microbiota, we are pleased to inform you that the 6th World
X THIS SUMMARY DOES NOT INCLUDE ! THIS SUMMARY INCLUDES
OPTIMIZING PNEUMOCOCCAL CONJUGATE VACCINES (PCV) SCHEDULES FOR CHILDREN IN VARIOUS AREAS OF THE WORLD What is the relative effect of administering PCV vaccines using a 3 primary doses (3p) versus 2 primary
2016/17 Vaccination and Immunisation list of additional services and enhanced services
2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services Version number: 1 First published:
XDR and MDR TB Urgent Research Priorities. Gerald Friedland MD Yale School of Medicine Nelson R Mandela School of Medicine
XDR and MDR TB Urgent Research Priorities Gerald Friedland MD Yale School of Medicine Nelson R Mandela School of Medicine The Year of MDR XDR TB CDC, WHO report on global XDR TB XDR TB defined Global distribution
OTC FOUNDATION LEADERSHIP FORUM
OTC FOUNDATION LEADERSHIP FORUM SALA PLENARIA MASCAGNI HOTEL LEON D ORO VERONA, 16 17 JUNE 2016 CO-CHAIRED BY JOERG FRANKE, PRESIDENT OTCF/GA GUIDO ROCCA, PRESIDENT OTC ITALY LIST OF FACULTY CO CHAIRMEN
Mayo Clinic Infectious Diseases Practice Updates Fairmont Orchid ~ Kamuela, Hawaii Salon 1 & 2 Monday, February 4 th ~ Friday, February 8 th, 2019
Sunday, February 3 Plaza #1 7:15 am Pre-Course Session Registration & Breakfast 7:45 am Optimizing Provider Potential: Beating Burnout Greg P. Couser, M.D., M.P.H. 12:00 pm Adjourn Monday, February 4 6:30
2018/19 Immunisation programmes list of additional and enhanced services
2018/19 Immunisation programmes list of additional and enhanced services 2018/19 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2018 Prepared
immunisation in New Zealand
This appendix details the history of. Section A1.1 is a brief summary of when each vaccine was introduced to the National Immunisation Schedule (the Schedule). This summary includes vaccines which were
Sami Bahna, Shreveport, LA (USA) Daniel Ein, Washington, DC (USA) Lawrence M. DuBuske, Gardner, MA (USA)
3 rd International Symposium: New Horizons in Treatment Modalities for Allergic & Immunologic Diseases SCIENTIFIC PROGRAM October 3-5, 2008 NH Laguna Palace, Mestre Venice, Italy Friday, October 3, 2008
Vaccine Media Trends Barometer December 2013
Vaccine Media Trends Barometer December 13 Geographic Activity Dec 1-31 13 Activity Summary December Alerts % of Total Report Vaccine Sentiment Negative 225 1.3% Neutral 92.5% Positive 137 81.2% Total
Vaccines including Tdap in pregnancy
Vaccines including Tdap in pregnancy Dr. Manish Sadarangani Director, Vaccine Evaluation Center, BC Children s Hospital Research Institute Assistant Professor, Division of Infectious Diseases, Department
21 st Century Vaccine Challenges
21 st Century Vaccine Challenges Presentation by Rosalyn Singleton MD, ANTHC Slides adapted from original powerpoint by: Carrie L. Byington, MD HA and Edna Benning Presidential Professor of Pediatrics
Brixia International Conference OPEN ISSUES IN THE CLINICAL AND THERAPEUTIC MANAGEMENT OF MAJOR PSYCHIATRIC DISORDERS
Brixia International Conference OPEN ISSUES IN THE CLINICAL AND THERAPEUTIC MANAGEMENT OF MAJOR PSYCHIATRIC DISORDERS Brescia, June 12 th -14 th, 2014 Congress Venue: Camera di Commercio, Via Einaudi 23,
Pneumococcal Disease and Pneumococcal Vaccines
Pneumococcal Disease and Epidemiology and Prevention of - Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at
Immunity and how vaccines work
Immunity and how vaccines work Dr Mary O Meara National Immunisation Office Objectives of session An understanding of the following principles Overview of immunity Different types of vaccines and vaccine
VACCINES FOR ADULTS. Developing an Underutilised Health Resource. 13 November 2007
VACCINES FOR ADULTS Developing an Underutilised Health Resource 13 November 2007 OUTLINE background to adult immunisation in Canada roles and recommendations of immunisation advisory committees in Canada
International Journal of Infectious Diseases
International Journal of Infectious Diseases 14 (2010) e197 e209 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Review
2009 DELPHE* Workshop in Infectious Diseases. August 10-14, Hanoi, Vietnam
2009 DELPHE* Workshop in Infectious Diseases August 10-14, Hanoi, Vietnam The National Institute of Hygiene & Epidemiology (NIHE) & Vabiotech (Company No. 1 for Vaccines and Biological Production) Monday
Cyprus Experience. Dr. Elena Papamichael Ministry of Health
Cyprus Experience Dr. Elena Papamichael Ministry of Health Cyprus became independent on1960. On 1974, Turkish troops invaded in the island disturbing the willing for peaceful living. Since then, Turkey
CUMULATIVE INVASIVE PNEUMOCOCCAL DISEASE CASE NUMBERS REPORTED BY THE GERMS-SA SURVEILLANCE PROGRAMME, 2005 TO DATE
CUMULATIVE INVASIVE PNEUMOCOCCAL DISEASE CASE NUMBERS REPORTED BY THE GERMS-SA SURVEILLANCE PROGRAMME, 5 TO DATE GERMS-SA surveillance programme http://www.nicd.ac.za/?page=germs-sa&id=97 National, active,
Preventing Vaccine-Preventable Diseases in HIV-Infected Children and Adults
Preventing Vaccine-Preventable Diseases in HIV-Infected Children and Adults 1. Objective The objectives of this chapter are to underline the role of vaccination in reducing morbidity and mortality in HIV
Activities in 2010, Priorities for 2011
European Centre for Disease Prevention and Control Activities in 2010, Priorities for 2011 Presentation to ENVI Committee by Marc Sprenger, Director ECDC 27 October 2010 Part 1: Examples of ECDC s work
Mandates and More. Julie Morita, M.D. Deputy Commissioner Chicago Department of Public Health. Chicago Department of Public Health
Mandates and More Julie Morita, M.D. Deputy Chicago Department of Public Health Why are vaccines required for school entry? School Vaccine Requirements Small pox vaccine required in Massachusetts 1855
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 October 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 October 2009 MENINGITEC suspension for injection in prefilled syringes meningococcal group C oligosaccharide conjugate
7 th INTERNATIONAL CONGRESS. President: Professor P.A. Grossi, Varese
7 th INTERNATIONAL CONGRESS President: Professor P.A. Grossi, Varese UNAHOTELS Varese 23-25 May 2019 Preliminary Program Thursday 23 th May 9,00-9,30 Welcome speech and introduction G. Bonelli (General
Family and Travel Vaccinations
Family and Travel Vaccinations We offer the full range of baby, child and family vaccinations. We are able to tailor schedules to your child s needs or international schedule. We have a suggested vaccination
Pneumococcal conjugate vaccine primes for polysaccharide inducible IgG2 antibody response in children with recurrent Otitis Media
Pneumococcal conjugate primes for IgG2 response Chapter 5a Pneumococcal conjugate vaccine primes for polysaccharide inducible IgG2 antibody response in children with recurrent Otitis Media Mijke A. Breukels,